Exactly. When you remove the patient group that experiences 90% of the severe cases, voila, your efficacy rate skyrockets.
Until SOMEONE ELSE completes trials on that missing age 55+ cohort, this vaccine should be accepted ONLY for ages 0 to 54. And given its likely low efficacy (62%), NOT for anyone with co-morbidities.
But that is also a selection bias. The very elderly or those who need lots of assistance in day to day lives or those with multiple comorbidities are much less likely to benefit from an ICU stay (ie they will likely die with or without support) so don’t get admitted at all.
Until SOMEONE ELSE completes trials on that missing age 55+ cohort, this vaccine should be accepted ONLY for ages 0 to 54. And given its likely low efficacy (62%), NOT for anyone with co-morbidities.